父は創業者、ジョヴァンニ・ステナヴァート。高校生のころより家業に積極的に携わる。1969年フェラーラ大学法学部卒業。入社後まもなく統率力を発揮。自身のキャリアを家業に捧げ、現在は名誉会長に就任。2007年イタリア大統領から起業家としての功績によりCavaliere del Lavoro（6等級）の功労勲章を受章。

父はセルジオ・ステナヴァート。1998年トリエステ大学政治学部卒業、2015年ケロッグ経営大学院のアドバンスト・マネジメント・プログラムに参加。大学時代サンゴバン社（フランス）の営業部門にて実績を積み、卒業後ファミリービジネスに加わり営業を担当。長く国際化、製品の多様化から管理プロセスの強化、イノベーション推進、構造改善など Stevanato Group の長期的ビジョンを牽引。また、意思決定サポートの効果的なインフラの構築、専門知識と見解からメリットを得るスキルベースの取締役会を推進し、コーポレートガバナンスの工場に貢献。 2010年から2020年までCEOを務め、2021年からは取締役会会長に就任。

ニューヨーク州立大学バッファロー校より化学工学の修士号、イーストカロライナ大学よりMBAを取得。2020年9月より、ナットクラッカーセラピューティックス社COO、mRNAセラピューティックス開発担当。2019年8月、前臨床段階のバイオテクノロジー企業であるADRx社CEO。1997年、アムジェン社入社、管理職を歴任し、2012年8月から2016年7月までアムジェン社のオペレーション担当エグゼクティブ・バイスプレジデントを務め、2017年1月、同職を退任。アムジェン入社前は、コプリー・ファーマシューティカルズ社（現在はテバ・ファーマシューティカル・インダストリーズの一部）およびバローズ・ウェルカム・カンパニー社（グラクソ・スミスクライン社の合併前の前身）にて指導的地位。現在、キャタレント社およびユニキュア社の取締役を務める。2018年からStevanato Group取締役会のメンバー。

Holding a doctorate in chemistry from the University of Florence, Italy, Fabrizio carried out postdoctoral work in physiological chemistry at the Massachusetts Institute of Technology. He is an alumnus of the Institute for International Management, Northwestern University, J.L. Kellogg Graduate School of Management and of the Executive Program in Manufacturing, Harvard University, Graduate School of Business Administration. He spent 25 years at Baxter International in Italy, Belgium, and the U.S. reaching the positions of corporate vice president Quality System and CVP Regulatory and Clinical Affairs. From 1999 to 2013, he served in senior executive roles at Amgen, including senior vice president, Quality and Compliance and corporate compliance officer, senior vice president, Manufacturing, and executive vice president, Operations. Currently, he is a member of the board of INCOG BioPharma Services. His past board memberships include UCLA’s Technology Development Corporation, XBiotech, where he chaired the Audit Committee, Menarini Biotech, and Theranos, where he chaired the Compliance and Quality Committee. He has been a member of the board of directors of Stevanato Group since 2013.

Fabio Buttignon (Belluno, 1959) is full professor of Advanced Corporate Finance at the University of Padua. Graduated at Ca’ Foscari University of Venice, where he also worked as researcher and associate professor. He has studied and carried out research at the University of California in Los Angeles (UCLA). He is the author of numerous national and international publications on strategy, finance and company valuation. He is a Chartered Accountant (CPA) and Auditor. He participates in corporate governance in listed and unlisted companies. He is founder and managing partner of Buttignon Zotti Milan & Co., an independent advisory boutique specialized in valuation, mergers and acquisitions, capital raising and financial restructuring. He has been a member of the board of directors of Stevanato Group since 2014.

ラトガース大学リビングストンカレッジ経済学学士（BA）取得、ラトガース大学よりプロフェッショナル・アカウンティングの経営学修士（MBA）を取得。米国公認会計士協会会員会計士。米国の上場企業であるスペシャルティ・ファーマシューティカルのジネルバ・ファーマシューティカルズ社取締役を務める。2015年からは監査委員会委員長を務める。 2003年から2018年の退職まで、最高財務責任者（CFO）としてNYSE上場のウエスト・ファーマシューティカル・サービシズに従事。2003年以前は主に製薬業界向けの公会計業務に20年以上従事。2021年5月からStevanato Group取締役会のメンバー。

Karen Flynn has more than 35 years of experience in the pharmaceutical services industry. She retired in October 2023 from the position of President, Biomodalities at Catalent Pharma Solutions, a position she held since April 2023. Prior to this, she was Senior Vice President and Chief Commercial Officer at Catalent until September 2022. She joined Catalent as President, Biologics and Chief Commercial Officer in January 2020 and held that position until October 2021. Before Catalent, Ms. Flynn was Senior Vice President and Chief Commercial Officer for West Pharmaceutical Services, Inc. from 2016 to 2019, and served as its President of Pharmaceutical Packaging Systems from 2014 and President of the Americas Packaging Systems business from 2012. Prior to this, she held a number of positions of increasing responsibility in technical, marketing and sales roles.
Ms. Flynn serves on the board of Quanterix Corporation (NASDAQ:QTRX), Sotera Health (NASDAQ: SHC), and a privately held company. She previously served on the boards of Recro Pharmaceuticals (NASDAQ:SCTL) from September 2015 to January 2020 and Catalent (NYSE:CTLT) from September 2022 to January 2024. She serves on the Board of Trustees for the Franklin Institute. Ms. Flynn holds a Master of Science in Business Administration from Boston University and a Master of Science in Engineering from the University of Pennsylvania. She received her Bachelor of Science in Pre-Professional Studies from the University of Notre Dame.
She has been a member of the board of directors of Stevanato Group since 2024.

Dr. Morel served as Chief Executive Officer of West from 2002 through 2015 and Chairman from 2003-2015. During his tenure revenues tripled and market capitalization increased more than twelve times. West was the top performing healthcare dividend stock on the NYSE over this time period. Prior to being named CEO he served as Chief Operating Officer and President of the Pharmaceutical Systems Division. His career at West started in 1992 as Director of R&D.
From 1984 to 1992 he worked in various positions developing technology for space based remote imaging and the Strategic Defense Initiative. He served as an advisor to NASA on a number of Space Station programs and in 1989 was selected by the Astronaut Office for training as a Mission Specialist. His research has been funded by NASA, the Office of Naval Research, the National Science Foundation, and DARPA.
Dr. Morel completed his undergraduate degree in Engineering at Lafayette College and his graduate studies at Cornell University in Materials Science and Veterinary Medicine and the Darden School of the University of Virginia. He received a D.Sc. (Hons) from Roanoke College.
Dr. Morel serves as a Director of Catalent Corporation (NYSE: CTLT), and the Stevanato Group SpA (NYSE:STVN). He is Chairman Emeritus of the Board of Trustees of the Franklin Institute in Philadelphia, PA and also chairs the Foundation Board of the American Oncologic Hospital of the Fox Chase Cancer Center. He is the founder of Progenitor Capital LLC and Chairs the Morel Family Foundation.
He has been a member of the board of directors of Stevanato Group since 2018.

Graduating in Chemical Engineering from the University of Padua in 1987, and holding an MBA from SDA Bocconi in Milan, Franco has gained significant experience managing global manufacturing companies for over 30 years. He has worked as plant director of FIS—Fabbrica Italiana Sintetici and then of Cambrex Profarmaco Milano, before taking over as Chief Executive Officer of FIS—Fabbrica Italiana Sintetici from 2010 to 2018. Franco joined Stevanato Group in 2019 as Chief Operating Officer and was appointed to Chief Executive Officer in February 2021 and served until May 2024. He has been a member of the board of directors of Stevanato Group since February 2021. 

After graduating in Business Administration at University Ca' Foscari of Venice, he spent his early years in international audit companies like Ernst & Young and Arthur Andersen.
He worked as Finance Director at IVG and then at Rossignol group. In 1996 he became Chief Operating Officer of Retail Brand Alliance (already Casual Corner group Inc.) where he remained until 1999 when he joined Luxottica Group S.p.A. as Vice President International Development. From 2001 to 2009 he was Chief Corporate Officer at Geox S.p.A., whilst in 2009 he became Chief Executive Officer for Stefanel S.p.A. He also served as an Independent Director of Luxottica Group S.p.A. from 2015 to 2020.
In 2013 he joined Moncler as Chief Corporate Officer. He is currently Executive Director of Moncler and Chief Corporate & Supply Officer of the Moncler Group; he is also Manager in Charge pursuant to Article 154-bis of the Consolidated Law on Finance.
He has been a member of the board of directors of Stevanato Group since 2024.

1997年パドヴァ大学法学部卒業、フォーダム大学（ニューヨーク）ロースクールより国際ビジネス・貿易法の修士号を取得。2000年ニューヨークにて、2001年イタリアにて弁護士資格を取得。2007年パドヴァに法律事務所、SAT Studio Legaleを開業。国際法律事務所シンプソン・サッチャー・アンド・バートレット（Simpson Thacher & Bartlett）のニューヨークオフィス、イタリアの法律事務所キオメンティ（Chiomenti）のミラノオフィスにて修習。2011年からStevanato Group取締役会のメンバー。

ルイージ・ボッコーニ商業大学（イタリア・ミラノ）経営学部、ミラノ大学政治学および社会学部を卒業。サクロ・クオーレ・カトリック大学（イタリア・ミラノ）より人事修士号取得。一流企業多数にて人事部長職を務め、HR（人事）分野において豊富な経験を持つ。2011年エンジーに入社、国際的な要職を務める。2019年7月からは同社、北・南・東ヨーロッパの最高人事責任者および安全衛生責任者（Health & Safety Officer）を務める。2021年5月からStevanato Group取締役会のメンバー。

父はセルジオ・ステナヴァート。1998年トリエステ大学政治学部卒業、2015年ケロッグ経営大学院のアドバンスト・マネジメント・プログラムに参加。大学時代サンゴバン社（フランス）の営業部門にて実績を積み、卒業後ファミリービジネスに加わり営業を担当。長く国際化、製品の多様化から管理プロセスの強化、イノベーション推進、構造改善など Stevanato Group の長期的ビジョンを牽引。また、意思決定サポートの効果的なインフラの構築、専門知識と見解からメリットを得るスキルベースの取締役会を推進し、コーポレートガバナンスの工場に貢献。 2010年から2020年までCEOを務め、2021年からは取締役会会長に就任。

Riccardo Butta holds a master’s degree in mechanical engineering from Politecnico in Milan, a degree in Business Management and Innovation from MIP in Milan and successfully completed the Executive Leadership Development Program from Stanford University in Palo Alto, California. Riccardo was the Senior Vice President of Flex Health Solutions, responsible for the global commercial organization of a Flex business unit providing contract design, manufacturing, and logistics services to the healthcare industry with focus on medical devices, drug delivery solutions, diagnostics and life sciences equipment. During his tenure at Flex, Riccardo was also responsible for the European organization of Flex Health Solutions, for the global device development organization, and for scale-up and management of the design center in Milan. In February 2022 Riccardo joined Stevanato Group as President Americas, overseeing the growth of the Group's in the area, as well as the expansion of the commercial offering around high value products and services

1997年、ヴェネツィア・カフォスカリ大学経営学部卒業。2020年CFOとしてStevanato Groupに入社。財務監査、財務、アドミニストレーション（／組織管理）、コンプライアンス、リスクマネジメントの分野において25年の経験を持ち、多国籍製造企業にて複数年計画やM&Aのコーディネートに従事。現在はアドミニストレーション（／組織管理）、財務、財務監査の統括にあたる。　

More than 25 years of international experience in the fast-moving consumer goods industry, both in family business and multinational
listed companies, developing and managing HR business partner organizations and people strategic plans to support the international
growth of the company, both organically and by acquisitions.
Paolo is responsible for developing and executing the Human Resources and Organization strategy to support Stevanato Group Business Plan and strategic direction, focusing on talent management, change management, organizational and performance development processes, succession planning, diversity & inclusion, while fostering Values & Guiding Principles adoption and Customer Centricity promotion.

Graduated from the Economics School of Turin and the Administrative School of Milan, he holds over 30 years of solid and diverse international management experience in the pharmaceutical and diagnostics industry. Ugo began his career in the family business in 1985. In 1995, he moved to Istituto Biologico Chemioterapico di Torino, where he became CEO of a Group company in 1998. Joining Diasorin in 2000 as Sales Director for the Italian market, he held various positions as Vice President on the Board of Assobiomedica and the European Diagnostic Manufacturers Association (EDMA). In 2012, he continued his career within Diasorin's Industrial Operations (EMEA), eventually becoming Senior Vice President of Corporate Industrial Operations in 2019. Following the spin-off of a business unit in July 2022, he assumed the CEO and General Manager role of the new subsidiary, Diasorin Italia S.p.A.. Ugo is currently Vice President of Assobiotec and was appointed Chief Operations Officer of Stevanato Group in March 2024.

1991年、ヴェネツィア・カフォスカリ大学経済学部卒業。SDAボッコーニ経営大学院（イタリア・ミラノ）にてMBAを取得。卒業後デロンギ社に入社、続くシーメンス社には10年勤務。2004年、Stevanato Groupに入社、2008年には事業開発の職務を遂行しながらCFOに昇進。2010年からは業務機能全般を直接担当するコーポレート・ジェネラル・マネージャーに就任。現在はチーフ・ビジネス・オフィサーとしてグループの戦略的事業開発、営業、製品管理、マーケティングおよび広報、ドラッグデリバリー・システム事業に従事。